I'm not as familiar with fintech, but the bio world is pretty different. There is an entire industry within venture focused solely on drug development, and this

I'm not as familiar with fintech, but the bio world is pretty different. There is an entire industry within venture focused solely on drug development, and this sector invests ~20% of all venture dollars. The recent entry of tech companies into this space may increase the number of startups and temper valuations (which is good), but many of the companies that tech VCs are funding are quite different than pure play biotechs that are funded by life sci specialists (and that have been generating market leading returns the last 5 years). More tech investment into bio won't kill the market as that market is supported by fundamental industry trends and specialist investors, but it could lead to bio-IT micro-bubbles